



Curriculum Vitae

Personal
information

Helena Isabel Fialho Florindo Roque Ferreira

Work experience

1. Employer: Faculty of Pharmacy, Univ Lisbon
 - Start date: 052005
 - End date: 102008
 - Position: Junior Assistant Lecturer
 - Country: Portugal
2. Employer: Faculty of Pharmacy, Univ Lisbon
 - Start date: 112008
 - End date: 102013
 - Position: Assistant Lecturer
 - Country: Portugal
3. Employer: Faculty of Pharmacy, Univ Lisbon
 - Start date: 112013
 - End date: 012018
 - Position: Assistant Lecturer with tenure
 - Country: Portugal
4. Employer: Faculty of Pharmacy, Univ Lisbon
 - Start date: 022018
 - End date: 092020
 - Position: Assistant Lecturer with tenure and habilitation
 - Country: Portugal
5. Employer: Research Institute for Medicines at the Faculty of Pharmacy, Univ of Lisbon
 - Start date: 032015
 - End date:
 - Position: Head of the BioNanoSciences – Drug Delivery & Immunotherapy Research Group
 - Activities:
 - Country: Portugal
 - Employer: Faculty of Pharmacy, Univ Lisbon
 - Start date: 102020
 - End date: 092023
 - Position: Associate Professor with tenure and habilitation
 - Country: Portugal
 - Employer: Faculty of Pharmacy, Univ Lisbon
 - Start date: 102023
 - End date: Present
 - Position: Full Professor
 - Country: Portugal

Education and
training

1. Subject: Faculty of Pharmacy, University of Lisbon; School of Pharmacy at the University of London
 - Start date: 102004
 - End date: 112008
 - Qualification: PhD
 - Organisation:
 - Country: Portugal
2. Subject: Faculty of Pharmacy, University of Lisbon
 - Start date: 091997
 - End date: 052003
 - Qualification: PharmD_ Pharmaceutical Sciences
 - Organisation:
 - Country: Portugal
3. Subject: Faculty of Pharmacy, University of Lisbon
 - Start date: 102023
 - End date:
 - Qualification: Full Professor
 - Country: Portugal

Additional
information

Publications

Publication summary: 65 manuscripts; 10 book chapters; >300 oral presentations; h_index 30. The full publication list is available through MyBibliography:
<https://www.ncbi.nlm.nih.gov/sites/myncbi/1hUyijhLv6gQw/bibliography/46640797/public/?sortBy=pubDate&sdirection=descending>
Researcher ID: E_7913_2012 | ORCID: 0000_0002_4006_5840 | Scopus Author ID: 24402599300 Selected scientific publications:
1. Conniot J*, Scomparin A*, Yeini E, Zupančič E, Peres C, Viana AS, Schwartz H, Erez N, Jung S, Satchi_Fainaro R#, Florindo HF#.

Immunisation with mannosylated nano_vaccine and inhibition of immune_suppressing microenvironment sensitizes melanoma to immune checkpoint modulators. *Nat Nanotechnology* (in press) (#senior author and corresponding author) 2. Zupančič E, Curato C, (...) Satchi_Fainaro R, Eisenbach L, Jung S, Florindo HF*. Nanoparticulate vaccine inhibits tumor growth via improved T cell recruitment into melanoma and huHER2 breast cancer. *Nanomedicine*. 2018 Apr;14(3):835_847. doi: 10.1016/j.nano.2017.12.011 3. Sainz V, Moura LIF, (...) Satchi_Fainaro R, F Florindo H.* α _Galactosylceramide and peptide_based nano_vaccine synergistically induced a strong tumor suppressive effect in melanoma. *Acta Biomater*. 2018 Aug;76:193_207. doi: 10.1016/j.actbio.2018.06.029. 4. Zupančič E, Curato C, (...) Satchi_Fainaro R, Jung S, Florindo HF*. Rational design of nanoparticles towards targeting antigen_presenting cells and improved T cell priming. *J Control Release* 2017; 28: 182_195. DOI: 10.1016/j.jconrel.2017.05.014 5. Silva JM, Zupancic E, Vandermeulen G, Oliveira V, Salgado A, Videira M, Gaspar M, Graça L, Prêat V*, Florindo HF*. In vivo delivery of peptides and Toll_like receptor ligands by mannose_functionalized polymeric nanoparticles induces prophylactic and therapeutic anti_tumour immune responses in a melanoma model. *J Control Release* 2015; 198C; 91_103. DOI: 10.1016/j.jconrel.2014.11.033.

Projects

Selected projects as a Principal Investigator: 1_ CoVax _ COVID_19 vaccine development; "La Caixa" Banking Foundation Health Research; Caixa Impulse program. Coordinator: Helena Florindo (FFUL, Portugal); PI Israel: Ronit Satchi_Fainaro. 2_ NanoPanTher: Sensitizing pancreatic cancer to immunotherapy with multimodal precision nanomedicines; "La Caixa" Banking Foundation Health Research Coordinator: Maria Vicent (CIPF, Valencia); PI Israel: Ronit Satchi_Fainaro; PI from Portugal: HF Florindo. 3_ MultiNano@MBM: Modulation of melanoma_stroma interactions using a rationally_designed nanomedicine combining BRAFi_, MEKi_ and immune_therapies; ERA_NET EuroNanoMed_II ENMed/0051/2016; Coordinator: Prof. Ronit Satchi_Fainaro (Tel Aviv University); PI from Portugal: HF Florindo. 4_ POINT4PAC: Precision Oncology by Innovative Therapies and Technologies; Portuguese National Science and Technology Foundation; Work Package leader; team member 5_ MultiNanoVac: Multidisciplinary strategy to develop novel multicomponent nanoscale systems for immune modulation; UT Austin_Portugal Program – Portuguese National Science and Technology Foundation; PI

Memberships

2015 – present Member, Controlled Release Society, USA; 2016 – present Member, European Association for Cancer Research (EACR); 2016 – present Member, Portuguese Association for Cancer Research (ASPIC); 2018 – present Director, Spanish_Portuguese Local Chapter; Spain/Portugal 2018 – 2021 Director, Focus Group on Nanomedicine and Nanoscale Drug Delivery (NNDD) at CRS. 2021 _ Co_chair, Focus Group on Nanomedicine and Nanoscale Drug Delivery (NNDD) at CRS. 2018 – External Reviewer, European Research Council (ERC), ERC Advanced Grants; 2018 – External Reviewer, Portuguese National Science and Technology Foundation (FCT), Portugal; 2018 – Reviewer, Czech Science Foundation, Czech Republic; 2017 – Reviewer, Netherlands Organization for Scientific Research; 2017 _ Reviewer, Worldwide Cancer Research (former AICR); 2016 _ Reviewer, The German Israeli Foundation for Scientific Research and Development & Israel Science Foundation, Israel; 2015 – Reviewer, Pfizer and National Medical Society Award; 2015 – Reviewer, Medical Research Council UK 2015 – Reviewer, Polish National Science Center; 2015 – Reviewer, FONDECYT_Chile Selected invited oral communications: 1_ Florindo HF. (2019) Nano_vaccines remodel tumor immune microenvironment, sensitizing solid tumors to Immune Checkpoint Therapy. CRS 2019, Valencia, Spain 2019 2_ Florindo HF. (2019) Nano_Vaccine Delivery Overcomes Resistance to Immune Checkpoint Therapy. Gordon Cancer nanotechnology, Mount Snow, USA 2019 3_ .Florindo HF. (2018) Impact of multicomponent nanosystems on immune cell modulation and immune checkpoint therapy for solid tumors. Nanomedicines seminar, University of Aveiro, Aveiro 2018 4_ Florindo, Helena (Univ Lisbon, Portugal) A Novel Multifunctional Polypeptide_Based Nanosystem As An Anti_Cancer Immunotherapeutic Approach For Melanoma. 12th International Symposium on Polymer Therapeutics: from Laboratory to Clinical Practice. 2018. Valencia. Spain.

Other Relevant Information